Breakthrough Drug Offers Hope for Patients with Rare Bleeding Disorder, Rendu-Osler Disease
A new treatment is offering a beacon of hope for individuals living with hereditary hemorrhagic telangiectasia (HHT), also known as Rendu-Osler disease, a rare genetic disorder characterized by abnormal blood vessel formation. An international clinical trial, with significant contributions from Spanish researchers, has demonstrated the effectiveness of engasertib in reducing the frequency and severity of nosebleeds – the most debilitating symptom of the disease.
HHT and the Burden of Chronic Bleeding
Affecting approximately one in 6,000 people, Rendu-Osler disease presents primarily as recurrent and often prolonged nosebleeds, frequently leading to severe anemia. Beyond the physical toll, patients frequently enough experience a significant emotional burden, frequently unseen by others. Until now, treatment options have been limited to drugs originally developed for other conditions, such as oncology, and often came with substantial side effects.
“People with HHT live with daily bleeding that can be vrey prolonged, with severe anemia and an associated emotional burden that is often invisible,” explained a researcher at the Bellvitge Biomedical Research Institute (IDIBELL). “Having a treatment that acts on the mechanism that causes the disease is a paradigm shift.”
Engasertib: A Targeted Approach
Engasertib represents a major advancement as the first molecule specifically designed to address the underlying biological mechanisms driving HHT. The rigorous clinical trial – international, double-blind, randomized, and placebo-controlled – confirmed that the drug significantly reduces both the duration and frequency of nosebleeds. Importantly, the data also indicate a favorable safety profile and improved patient tolerance.
“For the first time we have a molecule created specifically for HHT,” stated a leading physician at Bellvitge University Hospital. “The data indicate that it is capable of modifying the course of the disease and reducing bleeding that most affects the quality of life of affected people.”
spanish Researchers Lead the Way
The Bellvitge University Hospital and IDIBELL played a pivotal role in this breakthrough. The hospital’s HHT unit, the largest in Spain serving approximately 500 patients, was the second-highest enrolling center globally, contributing 23 of the 75 participants in the trial. The team also actively participated in the research protocol’s design.
This achievement underscores the importance of specialized multidisciplinary teams in tackling rare diseases, according to a senior official at Bellvitge Hospital. While engasertib is not yet approved for widespread use, these results provide the strongest evidence to date and pave the way for further studies aimed at securing its approval as the first dedicated treatment for HHT.
Why, Who, What, and How did it end?
Why: Researchers sought a targeted treatment for Hereditary Hemorrhagic Telangiectasia (HHT), a rare genetic disorder causing frequent and debilitating nosebleeds and anemia. Existing treatments were inadequate and often had significant side effects.
Who: the breakthrough was led by an international team of researchers, with significant contributions from the Bellvitge University Hospital and IDIBELL in Spain.The trial involved 75 participants globally, with 23 enrolled at the Bellvitge HHT Unit.
What: the clinical trial demonstrated the effectiveness of engasertib, a new drug specifically designed to address the underlying biological mechanisms of HHT. The drug significantly reduced the frequency and duration of nosebleeds, with a favorable safety profile.
How did it end?: The trial concluded with positive results, showing engasertib’s efficacy.
